Travere Therapeutics Inc (TVTX)
5.39
-0.06
(-1.10%)
USD |
NASDAQ |
Apr 25, 16:00
5.45
+0.06
(+1.11%)
Pre-Market: 07:59
Travere Therapeutics Enterprise Value: 220.58M for April 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 25, 2024 | 220.58M |
| April 24, 2024 | 225.15M |
| April 23, 2024 | 247.22M |
| April 22, 2024 | 255.59M |
| April 19, 2024 | 245.70M |
| April 18, 2024 | 251.78M |
| April 17, 2024 | 266.24M |
| April 16, 2024 | 278.42M |
| April 15, 2024 | 291.35M |
| April 12, 2024 | 295.16M |
| April 11, 2024 | 319.51M |
| April 10, 2024 | 317.99M |
| April 09, 2024 | 332.45M |
| April 08, 2024 | 340.06M |
| April 05, 2024 | 346.15M |
| April 04, 2024 | 339.30M |
| April 03, 2024 | 341.58M |
| April 02, 2024 | 346.15M |
| April 01, 2024 | 366.69M |
| March 28, 2024 | 397.13M |
| March 27, 2024 | 394.09M |
| March 26, 2024 | 386.48M |
| March 25, 2024 | 395.61M |
| March 22, 2024 | 410.07M |
| March 21, 2024 | 426.05M |
| Date | Value |
|---|---|
| March 20, 2024 | 400.94M |
| March 19, 2024 | 379.63M |
| March 18, 2024 | 356.80M |
| March 15, 2024 | 380.39M |
| March 14, 2024 | 383.43M |
| March 13, 2024 | 430.61M |
| March 12, 2024 | 400.18M |
| March 11, 2024 | 418.44M |
| March 08, 2024 | 469.42M |
| March 07, 2024 | 473.23M |
| March 06, 2024 | 465.62M |
| March 05, 2024 | 422.24M |
| March 04, 2024 | 433.66M |
| March 01, 2024 | 409.31M |
| February 29, 2024 | 385.72M |
| February 28, 2024 | 403.22M |
| February 27, 2024 | 442.79M |
| February 26, 2024 | 420.72M |
| February 23, 2024 | 414.63M |
| February 22, 2024 | 408.55M |
| February 21, 2024 | 410.07M |
| February 20, 2024 | 440.51M |
| February 16, 2024 | 434.42M |
| February 15, 2024 | 475.51M |
| February 14, 2024 | 432.19M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
150.98M
Minimum
Nov 09 2023
1.710B
Maximum
Feb 26 2021
906.30M
Average
920.92M
Median
Aug 18 2021
Enterprise Value Benchmarks
| AtriCure Inc | 1.002B |
| Bio-Rad Laboratories Inc | 7.452B |
| Artivion Inc | 1.084B |
| Shockwave Medical Inc | 12.04B |
| Perspective Therapeutics Inc | 931.55M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -90.17M |
| Revenue (Quarterly) | 45.06M |
| Total Expenses (Quarterly) | 127.90M |
| EPS Diluted (Quarterly) | -1.18 |
| Gross Profit Margin (Quarterly) | 89.87% |
| Profit Margin (Quarterly) | -200.1% |
| Earnings Yield | -29.87% |
| Normalized Earnings Yield | -83.74 |